tiprankstipranks
Vaxcyte, Inc. (DE:5VA)
NASDAQ:5VA
Germany Market
5VA
Vaxcyte
RESEARCH TOOLSreports

Vaxcyte (5VA) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

5VA Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Vaxcyte
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

5VA Stock 12 Month Forecast

Average Price Target

€101.70
▲(103.41% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Vaxcyte in the last 3 months. The average price target is €101.70 with a high forecast of €142.91 and a low forecast of €65.76. The average price target represents a 103.41% change from the last price of €50.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"€23","53":"€53","83":"€83","113":"€113","143":"€143"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":142.91187837,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€142.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.70415884,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€101.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65.75699925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€65.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,53,83,113,143],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.6,56.77783679769231,63.95567359538462,71.13351039307693,78.31134719076924,85.48918398846155,92.66702078615386,99.84485758384616,107.02269438153847,114.20053117923078,121.3783679769231,128.5562047746154,135.73404157230772,{"y":142.91187837,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.6,53.60801221846154,57.61602443692308,61.624036655384614,65.63204887384616,69.64006109230769,73.64807331076923,77.65608552923078,81.66409774769231,85.67210996615384,89.68012218461539,93.68813440307693,97.69614662153847,{"y":101.70415884,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.6,50.84284609615385,52.0856921923077,53.328538288461544,54.571384384615385,55.81423048076923,57.05707657692308,58.29992267307693,59.542768769230776,60.785614865384616,62.02846096153847,63.27130705769231,64.51415315384617,{"y":65.75699925,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€142.91Average Price Target€101.70Lowest Price Target€65.76
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on DE:5VA
Joseph Stringer
Needham
Needham
€96.44
Buy
92.89%
Upside
Reiterated
06/26/26
Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Vaxcyte (NASDAQ: PCVX)
Mizuho Securities Analyst forecast on DE:5VA
Salim Syed
Mizuho Securities
Mizuho Securities
€142.91
Buy
185.82%
Upside
Reiterated
06/18/26
Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)
Guggenheim Analyst forecast on DE:5VA
Seamus Fernandez
Guggenheim
Guggenheim
€101.7
Buy
103.41%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Vaxcyte (NASDAQ: PCVX) and BeOne Medicines (NASDAQ: ONC)
Evercore ISI Analyst forecast on DE:5VA
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Bank of America Securities Analyst forecast on DE:5VA
Jason Gerberry
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (NASDAQ: EVO), Vaxcyte (NASDAQ: PCVX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
TD Cowen Analyst forecast on DE:5VA
Tara Bancroft
TD Cowen
TD Cowen
€65.76
Buy
31.51%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and Cross Country Healthcare (NASDAQ: CCRN)
BTIG Analyst forecast on DE:5VA
Thomas Shrader
BTIG
BTIG
€78.03
Buy
56.06%
Upside
Reiterated
03/02/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vaxcyte (NASDAQ: PCVX), Universal Health (NYSE: UHS) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
Goldman Sachs Analyst forecast on DE:5VA
Asad Haider
Goldman Sachs
Goldman Sachs
€33.32→€58.74
Hold
17.49%
Upside
Reiterated
02/26/26
Vaxcyte price target raised to $67 from $38 at Goldman SachsVaxcyte price target raised to $67 from $38 at Goldman Sachs
Jefferies Analyst forecast on DE:5VA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€128.01
Buy
156.01%
Upside
Reiterated
02/25/26
Jefferies Reaffirms Their Buy Rating on Vaxcyte (PCVX)
Leerink Partners Analyst forecast on DE:5VA
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
10/01/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on DE:5VA
Joseph Stringer
Needham
Needham
€96.44
Buy
92.89%
Upside
Reiterated
06/26/26
Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Vaxcyte (NASDAQ: PCVX)
Mizuho Securities Analyst forecast on DE:5VA
Salim Syed
Mizuho Securities
Mizuho Securities
€142.91
Buy
185.82%
Upside
Reiterated
06/18/26
Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)
Guggenheim Analyst forecast on DE:5VA
Seamus Fernandez
Guggenheim
Guggenheim
€101.7
Buy
103.41%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Vaxcyte (NASDAQ: PCVX) and BeOne Medicines (NASDAQ: ONC)
Evercore ISI Analyst forecast on DE:5VA
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and BioMarin Pharmaceutical (NASDAQ: BMRN)
Bank of America Securities Analyst forecast on DE:5VA
Jason Gerberry
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (NASDAQ: EVO), Vaxcyte (NASDAQ: PCVX) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
TD Cowen Analyst forecast on DE:5VA
Tara Bancroft
TD Cowen
TD Cowen
€65.76
Buy
31.51%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Vaxcyte (NASDAQ: PCVX) and Cross Country Healthcare (NASDAQ: CCRN)
BTIG Analyst forecast on DE:5VA
Thomas Shrader
BTIG
BTIG
€78.03
Buy
56.06%
Upside
Reiterated
03/02/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vaxcyte (NASDAQ: PCVX), Universal Health (NYSE: UHS) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
Goldman Sachs Analyst forecast on DE:5VA
Asad Haider
Goldman Sachs
Goldman Sachs
€33.32→€58.74
Hold
17.49%
Upside
Reiterated
02/26/26
Vaxcyte price target raised to $67 from $38 at Goldman SachsVaxcyte price target raised to $67 from $38 at Goldman Sachs
Jefferies Analyst forecast on DE:5VA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€128.01
Buy
156.01%
Upside
Reiterated
02/25/26
Jefferies Reaffirms Their Buy Rating on Vaxcyte (PCVX)
Leerink Partners Analyst forecast on DE:5VA
David Risinger
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
10/01/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vaxcyte

3 Months
Joseph StringerNeedham
Success Rate
21/34 ratings generated profit
62%
Average Return
+12.94%
Copying Joseph Stringer's trades and holding each position for 3 Months would result in 61.76% of your transactions generating a profit, with an average return of +12.94% per trade.
1 Year
Thomas ShraderBTIG
Success Rate
15/21 ratings generated profit
71%
Average Return
+32.54%
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +32.54% per trade.
2 Years
Joseph StringerNeedham
Success Rate
24/34 ratings generated profit
71%
Average Return
+82.99%
Copying Joseph Stringer's trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +82.99% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5VA Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
10
8
4
7
6
Buy
3
3
4
3
3
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
12
8
10
9
In the current month, 5VA has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 5VA average Analyst price target in the past 3 months is 101.70.
Each month's total comprises the sum of three months' worth of ratings.

5VA Financial Forecast

5VA Earnings Forecast

Next quarter’s earnings estimate for 5VA is -€1.80 with a range of -€2.23 to -€1.29. The previous quarter’s EPS was -€2.01. 5VA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 5VA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 5VA is -€1.80 with a range of -€2.23 to -€1.29. The previous quarter’s EPS was -€2.01. 5VA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 5VA has Performed in-line its overall industry.
No data currently available

5VA Sales Forecast

Next quarter’s sales forecast for 5VA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 5VA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 5VA has Performed in-line its overall industry.
Next quarter’s sales forecast for 5VA is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 5VA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 5VA has Performed in-line its overall industry.

5VA Stock Forecast FAQ

What is DE:5VA’s average 12-month price target, according to analysts?
Based on analyst ratings, Vaxcyte, Inc.’s 12-month average price target is 101.70.
    What is DE:5VA’s upside potential, based on the analysts’ average price target?
    Vaxcyte, Inc. has 103.41% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vaxcyte, Inc. a Buy, Sell or Hold?
          Vaxcyte, Inc. has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Vaxcyte, Inc.’s share price target?
            The average share price target for Vaxcyte, Inc. is 101.70. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €142.91 ,and the lowest forecast is €65.76. The average share price target represents 103.41% Increase from the current price of €50.
              What do analysts say about Vaxcyte, Inc.?
              Vaxcyte, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of Vaxcyte, Inc.?
                To buy shares of DE:5VA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.